Haemonetics Corporation (NYSE: HAE) shares plunged 5.08% in Friday's intraday trading session, underperforming the broader market. The steep decline came after the medical device company reported disappointing third-quarter fiscal 2025 earnings results that missed analysts' expectations.
For the quarter ended December 31, 2024, Haemonetics posted revenue of $348.5 million, up 3.7% year-over-year but missing Wall Street's consensus estimate by 1.2%. Earnings per share came in at $0.75, a 20% increase from the prior year but falling short of analysts' projections by 18%.
Following the earnings release, several Wall Street analysts downgraded their ratings and price targets on Haemonetics. Bank of America lowered its rating to Underperform from Neutral and slashed its price target to $68 from $95, citing concerns over the revenue miss. Barrington Research and JMP Securities maintained their Outperform and Overweight ratings, respectively, but reduced their price targets on the stock.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。